{"id":4949,"date":"2020-02-04T09:32:52","date_gmt":"2020-02-04T09:32:52","guid":{"rendered":"http:\/\/localhost:8888\/biotech\/?page_id=4949"},"modified":"2023-11-24T13:36:18","modified_gmt":"2023-11-24T13:36:18","slug":"animal-welfare","status":"publish","type":"page","link":"https:\/\/dev.interpharma.animalwelfare.bertastrasse1.ch\/en\/","title":{"rendered":"Animal Welfare Report"},"content":{"rendered":"\n

Foreword<\/strong><\/h2>\n\n\n\n

3Rs 2.0: refining, reducing and replacing animal experiments with the aid of digitalisation<\/h2>\n\n\n\n

By focusing on \u00ab3R 2.0\u00bb, Interpharma wants to initiate a discussion on the possibilities offered by digitalisation with the aim of seeing a further substantial reduction in animal experiments. Data platforms and big data, in combination with artificial intelligence (AI), have the potential to reduce the number of animal experiments, replace them or refine the quality of those experiments that are still unavoidable. By collecting and analysing large volumes of data, researchers can gain important insights that enable them to develop and validate alternative methods. Data platforms can also be used to collect and share information on animal experiments that have already been carried out for the purpose of medical research. Networking in this way can prevent experiments from being repeated. Furthermore, data analyses can identify patterns and connections, meaning that animal experiments can be conducted in a more targeted and efficient manner. But data alone is not enough to replace or reduce animal experiments. Data experts and researchers are needed to draw the right conclusions from this data. With a view to ensuring new active substances are safe, ethical aspects must also be considered before these substances are used in clinical trials on humans.<\/p>\n\n\n\n

Intellectual property needs to remain protected<\/strong><\/h2>\n\n\n\n

If data from preclinical studies is to be shared widely, the protection of intellectual property must be taken into account. Companies and researchers invest a lot of time, money and resources in developing new treatments and drugs. So when data is exchanged, suitable measures need to be taken to ensure that intellectual property is appropriately protected. This can be done by concluding confidentiality agreements or using secure data platforms with suitable access and security controls, for example. It is vital that all parties involved in platform projects understand the importance of protecting intellectual property and take appropriate precautions to safeguard the rights of all those involved.<\/p>\n\n\n\n

We are convinced that the opportunities presented by data platforms, big data and artificial intelligence have the potential to help us make progress in the 3Rs too. Let\u2019s start talking about it!<\/p>\n\n\n\n

Other strategic issues on our platform<\/strong><\/h2>\n\n\n\n

In another focal topic, we highlight the connection between human and animal health, and the associated One Health approach. And finally, Birgit Ledermann, Novartis Global Animal Welfare and Compliance 3Rs Leader, explains in an interview what role the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) plays in improving standards in responsible research with animals worldwide. We hope you find our articles interesting.<\/p>\n\n\n\n

Best regards,<\/p>\n\n\n\n

\n
\n \n \n
\n

Dr. Ren\u00e9 P. Buholzer<\/p>\n

CEO, Interpharma<\/p>\n <\/div>\n <\/div>\n <\/section>\n\n